INFORMATION SOURCES "About Antimicrobial Resistance." Centers for Disease Control and Prevention. Centers for Disease Control and Prevention, 06 Apr. 2017. Web. 17 Apr. 2017.
Arias, Cesar A. , M.D./ PhD, and Barbra E. Murray, M.D. "A New Antibiotic and the Evolution of Resistance." The New England Journal of Medicine 372.12 (2015): 1168-170. Web. DOI: 10.1056/NEJMcibr1500292 “CDC: 1 in 3 antibiotic prescriptions unnecessary.” Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, 1 Jan. 2016, www.cdc.gov/media/releases/2016/p0503-unnecessary-prescriptions.html. Accessed 12 Apr. 2017.
Clatworthy, Anne E., Emily Pierson, and Deborah T. Hung. "Targeting virulence: a new paradigm for antimicrobial therapy." Nature chemical biology 3.9 (2007): 541-548.
Giltrap AM, et al. “Total Synthesis of Teixobactin.” Organic Letters, vol. 18, no. 11, 2016, pp. 2788–91., doi:10.1021/acs.orglett.6b01324.
Jin K, et al. “Total Synthesis of Teixobactin.” Nature Communications, vol. 7, 2016, pp. 12394–12394., doi:10.1038/ncomms12394.
Ling, Losee L. et al. “A new antibiotic kills pathogens without detectable resistance.” Nature , vol. 517, 2015, pp. 445–459. DOI: 10.1038/nature14098
“MRSA infection Symptoms.” Mayo Clinic, Mayo Foundation for Medical Education and Research, 9 Sept. 2015, www.mayoclinic.org/diseases-conditions/mrsa/basics/symptoms/con-20024479. Accessed 29 Mar. 2017.
Pantosti, A., and M. Venditti. “What is MRSA?” European Respiratory Journal, vol. 34, no. 5, 2009, pp. 1190–1196. DOI: 10.1183/09031936.00007709 “Tuberculosis (TB).” World Health Organization, World Health Organization, 25 Jan. 2017, www.who.int/mediacentre/factsheets/fs104/en/. Accessed 17 Apr. 2017.
Ventola, C. Lee. "The antibiotic resistance crisis: part 1: causes and threats." Pharmacy and Therapeutics 40.4 (2015): 277.